Advertisement News Archives - Page 1474 of 5234 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

August 27, 2026

FDA grants RPDD to ReviR’s RTX-117 for CMT

ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).

FDA grants RPDD to ReviR’s RTX-117 for CMT